Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

Blennow, O; Remberger, M; Klingspor, L; Omazic, B; Fransson, K; Ljungman, P; Mattsson, J; Ringdén, O

Blennow, O; Remberger, M; Klingspor, L; Omazic, B; Fransson, K; Ljungman, P; Mattsson, J; Ringdén, O.

Affiliation

Blennow O; Division of Infectious Diseases, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. Ola.Blennow@karolinska.se

Bone Marrow Transplant ; 45(12): 1710-8, 2010 Dec.

Article in En | MEDLINE | ID: mdl-20190840

Subject(s)

Amphotericin B/therapeutic use; Antifungal Agents/therapeutic use; Hematopoietic Stem Cell Transplantation/adverse effects; Mycoses/drug therapy; Mycoses/microbiology; Adolescent; Adult; Aged; Aspergillosis/drug therapy; Aspergillosis/etiology; Aspergillosis/microbiology; Aspergillus/genetics; Aspergillus/isolation & purification; Candida/genetics; Candida/isolation & purification; Candidiasis/drug therapy; Candidiasis/etiology; Candidiasis/microbiology; Child; Female; Humans; Male; Middle Aged; Mycoses/etiology; Polymerase Chain Reaction/methods; Prospective Studies; Risk Factors; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Amphotericin B / Hematopoietic Stem Cell Transplantation / Mycoses / Antifungal Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google